Biovica, a leader in blood-based cancer monitoring, today announced that the company has entered into a commercial agreement (client bill agreement) with a leading U.S. NCI-designated Comprehensive Cancer Center. The agreement enables clinicians at the institution to order DiviTum® TKa, Biovica’s FDA-cleared blood-based biomarker test, for clinical use in breast cancer.
The agreement streamlines ordering and billing processes and aligns with the cancer center’s precision oncology initiatives. The adoption of DiviTum TKa improves access to treatment monitoring for patients receiving CDK4/6 inhibitor therapy and creates the foundation for a potential, stepwise expansion of clinical use over time.
“Entering into a commercial agreement with an NCI-designated Comprehensive Cancer Center of this caliber is an important step in our U.S. commercialization efforts. The decision to adopt DiviTum TKa in clinical practice confirms the clinical value of the test. The collaboration strengthens our position among leading academic cancer centers and provides a strong foundation for continued clinical and commercial expansion in the U.S.,” said Anders Rylander, CEO of Biovica.
The agreement strengthens Biovica’s presence among leading U.S. cancer institutions and establishes an additional reference institution for DiviTum TKa. This supports increased confidence among clinicians and strengthens the company’s dialogue with healthcare networks and payers, collectively paving the way for broader integration of the biomarker into clinical practice in the U.S.